[go: up one dir, main page]

PE20020908A1 - Produccion recombinante de polimeros polianionicos y uso de de los mismos - Google Patents

Produccion recombinante de polimeros polianionicos y uso de de los mismos

Info

Publication number
PE20020908A1
PE20020908A1 PE2002000216A PE2002000216A PE20020908A1 PE 20020908 A1 PE20020908 A1 PE 20020908A1 PE 2002000216 A PE2002000216 A PE 2002000216A PE 2002000216 A PE2002000216 A PE 2002000216A PE 20020908 A1 PE20020908 A1 PE 20020908A1
Authority
PE
Peru
Prior art keywords
polypeptide
polymer
polyanionic
interferon
vintage
Prior art date
Application number
PE2002000216A
Other languages
English (en)
Inventor
David W Leung
Philip A Bergman
Gregory E Pietz
Waggoner
Christopher K Tompkins
Alan Lofquist
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Publication of PE20020908A1 publication Critical patent/PE20020908A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE REFIERE A UNA PROTEINA DE FUSION RECOMBINANTE QUE COMPRENDE UN PRIMER POLIPEPTIDO EN EL EXTREMO AMINO-TERMINAL DE DICHO POLIPEPTIDO POLIANIONICO Y UN SEGUNDO POLIPEPTIDO EN EL EXTREMO CARBOXILO-TERMINAL. LOS POLIPEPTIDOS SE SELECCIONAN DEL GRUPO FORMADO POR UN POLIPEPTIDO DIRECCIONADOR Y UN POLIPEPTIDO TERAPEUTICO. LA PROTEINA DE FUSION COMPRENDE OTRO POLIPEPTIDO SELECCIONADO DE INTERFERON, O-INTERFERON, ß-INTERFERON, FACTOR ESTIMULADOR DE COLONIAS DE GRANULOCITOS, ENTRE OTROS. LOS POLIMEROS POLIANIONICOS PUEDEN MEJORAR LAS PROPIEDADES DE BIOACTIVIDAD Y SOLUBILIDAD EN AGUA DE UNA DROGA A LA CUAL ESTAN UNIDOS. SE REFIERE TAMBIEN A UNA PREPARACION MONODISPERSA DE UN POLIMERO POLIANIONICO PRODUCIDO DE FORMA RECOMBINANTE QUE SE PUEDE MANIPULAR CON FACILIDAD TAL COMO EXTENDER SU LONGITUD, LA PORCION ACTIVA SE PUEDE UNIR QUIMICAMENTE O DE FORMA RECOMBINANTE AL POLIMERO POLIANIONICO PARA INCREMENTAR SU VIDA MEDIA BILOLOGICA Y/O SOLUBILIDAD Y DIRECCIONAR LA DISTRIBUCION DE UN CONJUGADO
PE2002000216A 2001-03-21 2002-03-20 Produccion recombinante de polimeros polianionicos y uso de de los mismos PE20020908A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27770501P 2001-03-21 2001-03-21

Publications (1)

Publication Number Publication Date
PE20020908A1 true PE20020908A1 (es) 2002-10-26

Family

ID=23062016

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000216A PE20020908A1 (es) 2001-03-21 2002-03-20 Produccion recombinante de polimeros polianionicos y uso de de los mismos

Country Status (4)

Country Link
US (3) US20020169125A1 (es)
AU (1) AU2002252429A1 (es)
PE (1) PE20020908A1 (es)
WO (1) WO2002077036A2 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1373470B1 (en) * 2001-02-20 2013-04-24 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US20030003048A1 (en) * 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
RU2316591C2 (ru) 2001-11-09 2008-02-10 Джорджтаун Юниверсити Новые изоформы ингибитора роста васкулярных эндотелиальных клеток
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
AU2003253048A1 (en) * 2002-07-09 2004-01-23 Morphochem Aktiengellschaft Fur Kombinatorische Chemie Tubulysin conjugates
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CN102532120A (zh) 2002-08-23 2012-07-04 索隆-基特林癌症研究协会 埃坡霉素(epothilone)，合成埃坡霉素的中间体，其类似物及其用途
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
AU2003272719A1 (en) * 2002-09-26 2004-04-19 Carbomer, Inc. Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents
FR2855521B1 (fr) * 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
PT1694363E (pt) * 2003-12-16 2014-02-20 Nektar Therapeutics Composições monodispersas de naloxol peguilado
US20070207139A1 (en) * 2004-06-10 2007-09-06 Saint Louis University, A Non-Profit Organization Enhancing the effect of therapeutic proteins on the central nervous system
US7863238B2 (en) * 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
US7972593B2 (en) 2004-06-10 2011-07-05 Saint Louis University Delivery of therapeutic agents to the bone
MX2007004662A (es) * 2004-10-18 2007-11-23 Globeimmune Inc Terapia basada en levaduras para infeccion cronica por hepatitis c.
FR2881140B1 (fr) * 2005-01-27 2007-04-06 Flamel Technologies Sa Copolyhydroxyalkylglutamines fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1929073A4 (en) * 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
AU2007223855B2 (en) † 2006-03-06 2013-05-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
FI2402754T4 (fi) † 2006-03-06 2023-10-06 Ei-kiinteärakenteisia rekombinantteja polymeerejä ja niiden käyttötapoja
CN101209350B (zh) * 2006-12-30 2011-09-07 中国人民解放军军事医学科学院毒物药物研究所 以氨基酸为连接子的多聚谷氨酸-药物偶合物
BRPI0815416A2 (pt) * 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
DE102008060549A1 (de) * 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
LT2393828T (lt) 2009-02-03 2017-01-25 Amunix Operating Inc. Prailginti rekombinantiniai polipeptidai ir juos apimančios kompozicijos
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CN101830984B (zh) * 2009-03-10 2013-10-09 上海市肺科医院 肿瘤诊断和治疗用的双靶向杂合多肽
JP5839597B2 (ja) * 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8394922B2 (en) * 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
AU2010290077C1 (en) 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
EP2502939B1 (en) 2009-11-19 2016-01-27 Zhejiang University Nonnatural collagen-like protein and use thereof
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
US9221882B2 (en) 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
CA2807266C (en) 2010-08-04 2020-03-24 Tixupharma Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair
DK2814840T3 (da) 2012-02-15 2020-02-03 Bioverativ Therapeutics Inc Faktor viii-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
US10370430B2 (en) 2012-02-15 2019-08-06 Bioverativ Therapeutics Inc. Recombinant factor VIII proteins
CA3179537A1 (en) 2012-02-27 2013-09-06 Amunix Pharmaceuticals, Inc. Xten conjugate compositions and methods of making same
EP3210627B1 (en) 2012-07-12 2022-12-21 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
SMT201700294T1 (it) 2013-02-14 2017-07-18 Bristol Myers Squibb Co Composti a base di tubulisina, metodi di produzione e uso
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
DE102014206051A1 (de) * 2014-03-31 2015-10-01 Henkel Ag & Co. Kgaa Proteasen mit verbesserter Wasserhärtetoleranz
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
JP6759326B2 (ja) 2015-07-12 2020-09-23 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 細胞結合分子の共役のための架橋連結体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR102659212B1 (ko) 2015-08-03 2024-04-18 바이오버라티브 테라퓨틱스 인크. 인자 ix 융합 단백질 및 이의 제조 방법 및 사용 방법
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
JP6758889B2 (ja) * 2016-04-07 2020-09-23 シスメックス株式会社 標的タンパク質の精製方法
KR20220147719A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
WO2018185131A2 (en) 2017-04-05 2018-10-11 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
JP2021507706A (ja) 2017-12-21 2021-02-25 アムニクス ファーマシューティカルズ， インコーポレイテッド 放出セグメントおよびそれを含む結合組成物
MX2020012397A (es) 2018-05-18 2021-04-12 Bioverativ Therapeutics Inc Metodos de tratamiento de la hemofilia a.
KR20220029725A (ko) 2019-06-29 2022-03-08 항저우 디에이씨 바이오테크 씨오, 엘티디 세포-결합 분자-튜불리신 유도체 접합체 및 이의 제조 방법
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
EP0738158B1 (en) * 1994-01-12 2002-04-03 Amersham plc Biological targeting agents
PL189698B1 (pl) * 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
DE19712718C2 (de) * 1997-03-26 1999-09-23 Asta Medica Ag Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
US6180084B1 (en) * 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
CA2311681A1 (en) * 1997-12-08 1999-06-17 Genentech, Inc. Human interferon-epsilon: a type i interferon

Also Published As

Publication number Publication date
AU2002252429A1 (en) 2002-10-08
US20050118136A1 (en) 2005-06-02
WO2002077036A2 (en) 2002-10-03
US20080176288A1 (en) 2008-07-24
WO2002077036A3 (en) 2004-01-29
US20020169125A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
PE20020908A1 (es) Produccion recombinante de polimeros polianionicos y uso de de los mismos
NO992102D0 (no) Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
BR0010750A (pt) Peptìdeos insulinotrópicos de longa duração
ES2721172T3 (es) Una nueva clase de moléculas terapéuticas a base de proteínas
PT1226110E (pt) Aminoacidos biciclicos como agentes farmaceuticos
CY1114244T1 (el) Σκευασματα ανταγωνιστη vegf καταλληλα για ενδοϋαλωδη χορηγηση
AR072596A1 (es) Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico
CO6351745A2 (es) Polipéptidos g-csf bovinos modificados y sus usos
WO2007022239A3 (en) Pharmaceutical formulations for sustained drug delivery
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
BR0112962B1 (pt) Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
AR056137A1 (es) Un conjugado peptido inmunoglobulina y su uso como antiviral
PE20030473A1 (es) Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular
EA200500632A1 (ru) Агрегат с повышенной способностью к деформации, содержащий по крайней мере три амфипатических соединения для лучшего проникновения через полунепроницаемые барьеры и для неинвазивного введения лекарственных средств in vivo в особенности через кожу
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
BR0206852A (pt) Conjugados de polìmero de neublastina e métodos para uso dos mesmos
RU2001132140A (ru) Рекомбинантный рецептор коллагена на тромбоцитах гликопротеин VI и его применение в фармацевтике
NO20073914L (no) Biologisk aktive peptider
DK1219301T3 (da) Vacciner, som indeholder hybridpolypeptider, der består af mindst to forskellige allergene proteiner
EP1446479A4 (en) RECOMBINANT ADENOVIRUS WITH ENHANCED THERAPEUTIC EFFECT AND PHARMACEUTICAL COMPOSITION COMPRISING SAID RECOMBINANT ADENOVIRUS
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
EP1578772A4 (en) CYTOKINS AND CYTOKIN RECEPTORS WITH REDUCED IMMUNOGENICITY
AR043216A1 (es) Esteres activados de polietilenglicol
ES2122921B1 (es) Proteinas recombinantes de fusion del virus reproductivo y respiratorio porcino (prrsv) y su empleo en diagnostico.
EP1411964A4 (en) PEPTIDES MODULATING BLOOD COAGULATION AND METHODS OF USE

Legal Events

Date Code Title Description
FD Application declared void or lapsed